163 related articles for article (PubMed ID: 37997518)
1. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Pratt E
Diabetes Obes Metab; 2024 Mar; 26(3):1137. PubMed ID: 37997518
[No Abstract] [Full Text] [Related]
2. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Pratt E; Ma X; Liu R; Robins D; Coskun T; Sloop KW; Haupt A; Benson C
Diabetes Obes Metab; 2023 Sep; 25(9):2642-2649. PubMed ID: 37264711
[TBL] [Abstract][Full Text] [Related]
3. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Pratt E; Ma X; Liu R; Robins D; Haupt A; Coskun T; Sloop KW; Benson C
Diabetes Obes Metab; 2023 Sep; 25(9):2634-2641. PubMed ID: 37344954
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Frias JP; Hsia S; Eyde S; Liu R; Ma X; Konig M; Kazda C; Mather KJ; Haupt A; Pratt E; Robins D
Lancet; 2023 Aug; 402(10400):472-483. PubMed ID: 37369232
[TBL] [Abstract][Full Text] [Related]
5. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Urva S; Coskun T; Loh MT; Du Y; Thomas MK; Gurbuz S; Haupt A; Benson CT; Hernandez-Illas M; D'Alessio DA; Milicevic Z
Lancet; 2022 Nov; 400(10366):1869-1881. PubMed ID: 36354040
[TBL] [Abstract][Full Text] [Related]
6. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Wharton S; Blevins T; Connery L; Rosenstock J; Raha S; Liu R; Ma X; Mather KJ; Haupt A; Robins D; Pratt E; Kazda C; Konig M;
N Engl J Med; 2023 Sep; 389(10):877-888. PubMed ID: 37351564
[TBL] [Abstract][Full Text] [Related]
7. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.
Alba M; Yee J; Frustaci ME; Samtani MN; Fleck P
Clin Obes; 2021 Apr; 11(2):e12432. PubMed ID: 33475255
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.
Asano M; Sekikawa A; Kim H; Gasser RA; Robertson D; Petrone M; Jermutus L; Ambery P
Diabetes Obes Metab; 2021 Aug; 23(8):1859-1867. PubMed ID: 33908687
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
Ono R; Furihata K; Ichikawa Y; Nakazuru Y; Bergman A; Gorman DN; Saxena AR
Diabetes Obes Metab; 2023 Mar; 25(3):805-814. PubMed ID: 36433713
[TBL] [Abstract][Full Text] [Related]
11. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Tillner J; Posch MG; Wagner F; Teichert L; Hijazi Y; Einig C; Keil S; Haack T; Wagner M; Bossart M; Larsen PJ
Diabetes Obes Metab; 2019 Jan; 21(1):120-128. PubMed ID: 30091218
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
Qin J; Song L
BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
[TBL] [Abstract][Full Text] [Related]
13. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
[TBL] [Abstract][Full Text] [Related]
14. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
[TBL] [Abstract][Full Text] [Related]
16. New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.
George C; Byun A; Howard-Thompson A
Am J Med; 2018 Nov; 131(11):1304-1306. PubMed ID: 29969616
[TBL] [Abstract][Full Text] [Related]
17. A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'.
Goldenberg RM
Diabetes Obes Metab; 2024 Mar; 26(3):1138-1141. PubMed ID: 38016705
[No Abstract] [Full Text] [Related]
18. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
Jungnik A; Arrubla Martinez J; Plum-Mörschel L; Kapitza C; Lamers D; Thamer C; Schölch C; Desch M; Hennige AM
Diabetes Obes Metab; 2023 Apr; 25(4):1011-1023. PubMed ID: 36527386
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
Wu J; Zhou R; Zhang Q; Zhang Q; Qin H; Ye Z; Xu Y; Feng S; Shu C; Shen Y; Fan Y; Wang Q; Du Y; Hu W
Diabetes Obes Metab; 2024 Mar; 26(3):901-910. PubMed ID: 38100147
[TBL] [Abstract][Full Text] [Related]
20. Delivery Device Patents on GLP-1 Receptor Agonists.
Alhiary R; Gabriele S; Kesselheim AS; Tu SS; Feldman WB
JAMA; 2024 Mar; 331(9):794-796. PubMed ID: 38315473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
